[go: up one dir, main page]

CO2018008173A2 - Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) - Google Patents

Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)

Info

Publication number
CO2018008173A2
CO2018008173A2 CONC2018/0008173A CO2018008173A CO2018008173A2 CO 2018008173 A2 CO2018008173 A2 CO 2018008173A2 CO 2018008173 A CO2018008173 A CO 2018008173A CO 2018008173 A2 CO2018008173 A2 CO 2018008173A2
Authority
CO
Colombia
Prior art keywords
disorders
rock
compounds
kinase inhibitors
related compounds
Prior art date
Application number
CONC2018/0008173A
Other languages
English (en)
Inventor
Wu Yang
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
Michael J Orwat
Vladimir Ladziata
Peter W Glunz
Ii Leon M Smith
Indawati Delucca
J P Donald Pinto
Scott A Shaw
Manoranjan Panda
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2018008173A2 publication Critical patent/CO2018008173A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula (I): (I) o estereoisómeros, tautómeros o sales del mismolos farmacéuticamente aceptables, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores de ROCK selectivos. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y a métodos para tratar trastornos cardiovasculares, trastornos relacionados con el músculo liso, trastornos oncológicos, trastornos neuropatológicos, trastornos autoinmunitarios, trastornos fibróticos y/o trastornos inflamatorios mediante su uso.
CONC2018/0008173A 2016-01-13 2018-08-01 Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) CO2018008173A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13
PCT/US2017/013323 WO2017123860A1 (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Publications (1)

Publication Number Publication Date
CO2018008173A2 true CO2018008173A2 (es) 2018-08-21

Family

ID=57907009

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0008173A CO2018008173A2 (es) 2016-01-13 2018-08-01 Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)

Country Status (29)

Country Link
US (2) US10611776B2 (es)
EP (2) EP3402790B1 (es)
JP (2) JP6976953B2 (es)
KR (1) KR102725741B1 (es)
CN (1) CN108699038B (es)
AR (1) AR107354A1 (es)
AU (2) AU2017206820B2 (es)
BR (1) BR112018013780B1 (es)
CA (1) CA3010900A1 (es)
CL (1) CL2018001899A1 (es)
CO (1) CO2018008173A2 (es)
CY (1) CY1124858T1 (es)
EA (1) EA036172B1 (es)
ES (1) ES2898698T3 (es)
HR (1) HRP20211888T1 (es)
HU (1) HUE057455T2 (es)
IL (1) IL260448B (es)
LT (1) LT3402790T (es)
MA (2) MA43862A (es)
MX (2) MX382434B (es)
PL (1) PL3402790T3 (es)
PT (1) PT3402790T (es)
RS (1) RS62690B1 (es)
SG (1) SG11201805927YA (es)
SI (1) SI3402790T1 (es)
SM (1) SMT202100660T1 (es)
TW (1) TWI730032B (es)
UY (1) UY37073A (es)
WO (1) WO2017123860A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242873B1 (en) 2015-01-09 2020-07-22 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Ｒｈｏ激酶（ＲＯＣＫ）抑制劑之內醯胺
UY37073A (es) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
CO2018008450A2 (es) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 ３－（（雜－）芳基）－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物
US20170197971A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
AU2017206909B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
JP6987792B2 (ja) 2016-05-27 2022-01-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン
JP6903731B2 (ja) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
CN109661396B (zh) 2016-07-07 2022-07-01 百时美施贵宝公司 作为rock抑制剂的螺稠合环状脲
KR102491994B1 (ko) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Rock의 억제제로서의 스피로락탐
EP3548468B1 (en) 2016-11-30 2020-09-16 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors
WO2019014303A1 (en) * 2017-07-12 2019-01-17 Bristol-Myers Squibb Company 5-OR 6,6-CHANNEL BICYCLIC CHAINS AND AMINOHETEROCYCLIC AMINOHETEROCYCLIC INHIBITORS FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
KR102680164B1 (ko) 2017-07-12 2024-07-01 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 페닐아세트아미드
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
US11192891B2 (en) 2017-11-03 2021-12-07 Bristol-Myers Squibb Company Diazaspiro ROCK inhibitors
ES3010282T3 (en) * 2018-04-17 2025-04-02 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN118434843A (zh) 2021-11-11 2024-08-02 学校法人同志社 角膜内皮细胞的冷冻保存制剂及其制造方法
JP7797234B2 (ja) 2022-02-18 2026-01-13 キヤノン株式会社 保持装置、リソグラフィ装置、および物品製造方法
CN119698408A (zh) * 2022-07-12 2025-03-25 安道麦马克西姆有限公司 制备取代的苯甲酰胺的方法
WO2024229439A2 (en) * 2023-05-03 2024-11-07 The University Of Chicago Inhibitors of nsun1- and nsun2-mediated active structures
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007142323A1 (ja) * 2006-06-08 2009-10-29 宇部興産株式会社 側鎖にスピロ環構造を有する新規インダゾール誘導体
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
EP2125745B1 (en) * 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
NZ586335A (en) * 2007-12-26 2011-08-26 Sanofi Aventis Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
SG190819A1 (en) 2010-11-15 2013-07-31 Abbvie Inc Nampt and rock inhibitors
US9926282B2 (en) 2013-01-18 2018-03-27 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
ES2633987T3 (es) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
ES2838573T3 (es) 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
EP3242873B1 (en) 2015-01-09 2020-07-22 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Ｒｈｏ激酶（ＲＯＣＫ）抑制劑之內醯胺
UY37073A (es) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
JP6987792B2 (ja) 2016-05-27 2022-01-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン
KR102491994B1 (ko) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Rock의 억제제로서의 스피로락탐
CN109661396B (zh) 2016-07-07 2022-07-01 百时美施贵宝公司 作为rock抑制剂的螺稠合环状脲
JP6903731B2 (ja) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
EP3548468B1 (en) 2016-11-30 2020-09-16 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors

Also Published As

Publication number Publication date
JP2022024019A (ja) 2022-02-08
CA3010900A1 (en) 2017-07-20
AU2017206820A1 (en) 2018-08-23
EP3402790B1 (en) 2021-10-06
AU2021221872A1 (en) 2021-09-23
WO2017123860A1 (en) 2017-07-20
EP3402790A1 (en) 2018-11-21
EP3954681A1 (en) 2022-02-16
HRP20211888T1 (hr) 2022-03-04
ES2898698T3 (es) 2022-03-08
JP6976953B2 (ja) 2021-12-08
JP2019509978A (ja) 2019-04-11
CN108699038A (zh) 2018-10-23
EA201891557A1 (ru) 2019-01-31
JP7268116B2 (ja) 2023-05-02
KR20180097749A (ko) 2018-08-31
KR102725741B1 (ko) 2024-11-01
AU2017206820B2 (en) 2021-06-17
RS62690B1 (sr) 2021-12-31
SI3402790T1 (sl) 2022-01-31
MA55633A (fr) 2022-02-16
SMT202100660T1 (it) 2022-01-10
CN108699038B (zh) 2021-04-16
PT3402790T (pt) 2021-11-22
US20190016735A1 (en) 2019-01-17
CY1124858T1 (el) 2022-11-25
US10611776B2 (en) 2020-04-07
HUE057455T2 (hu) 2022-05-28
US20200131200A1 (en) 2020-04-30
LT3402790T (lt) 2021-12-10
MX2018008219A (es) 2018-09-07
TW201726619A (zh) 2017-08-01
CL2018001899A1 (es) 2018-11-09
US10829501B2 (en) 2020-11-10
IL260448B (en) 2020-09-30
PL3402790T3 (pl) 2022-01-24
SG11201805927YA (en) 2018-08-30
MX382434B (es) 2025-03-13
MA43862A (fr) 2021-06-02
EA036172B1 (ru) 2020-10-09
BR112018013780B1 (pt) 2023-12-19
MX2021005311A (es) 2021-06-23
AR107354A1 (es) 2018-04-18
UY37073A (es) 2017-07-31
TWI730032B (zh) 2021-06-11
BR112018013780A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
CO2018008173A2 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
MX2017000485A (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock).
AR103895A1 (es) Lactamas como inhibidores de rock
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
CO2019014455A2 (es) Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock
CO2017003833A2 (es) Pirimidinonas como inhibidores del factor xia
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201691512A1 (ru) Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы